Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly Moy

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Cancer|November 14, 2023
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trialJingran Ji, Marie Bae, Can-Lan Sun, et al.
Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast CancerRachel O Abelman, Bogang Wu, Haley Barnes, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2024
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective studyMina S Sedrak, Can-Lan Sun, Marie Bae, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
JCO Global Oncology|January 11, 2024
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified GuidelineSana Al Sukhun, Sarah Temin, Carlos H Barrios, et al.
The New England Journal of Medicine|January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerSara M Tolaney, William T Barry, Chau T Dang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Sheng Sun, Nayana Thimmiah, et al.
NPJ Precision Oncology|July 26, 2019
Blood-based monitoring identifies acquired and targetable driver <i>HER2</i> mutations in endocrine-resistant metastatic breast cancerArielle J Medford, Taronish D Dubash, Dejan Juric, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Cancer|November 14, 2023
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trialJingran Ji, Marie Bae, Can-Lan Sun, et al.
Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast CancerRachel O Abelman, Bogang Wu, Haley Barnes, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2024
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective studyMina S Sedrak, Can-Lan Sun, Marie Bae, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
JCO Global Oncology|January 11, 2024
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified GuidelineSana Al Sukhun, Sarah Temin, Carlos H Barrios, et al.
The New England Journal of Medicine|January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerSara M Tolaney, William T Barry, Chau T Dang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Sheng Sun, Nayana Thimmiah, et al.
NPJ Precision Oncology|July 26, 2019
Blood-based monitoring identifies acquired and targetable driver <i>HER2</i> mutations in endocrine-resistant metastatic breast cancerArielle J Medford, Taronish D Dubash, Dejan Juric, et al.
Pageof 17